Literature DB >> 32238358

Clinical Research Slows as COVID-19 Surges.

.   

Abstract

As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2020        PMID： 32238358     DOI： 10.1158/2159-8290.CD-NB2020-021

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

Review 1.  The Impact of COVID-19 on National Clinical Trials Network Breast Cancer Trials.

Authors:  Amara Ndumele; Ko Un Park
Journal:  Curr Breast Cancer Rep       Date:  2021-05-12

Review 2.  Review on the Oncology Practice in the Midst of COVID-19 Crisis: The Challenges and Solutions.

Authors:  Pedram Fadavi; Mohammad Houshyari; Amir Shahram Yousefi Kashi; Alireza Mosavi Jarrahi; Farnaz Roshanmehr; Mohammad Ali Broomand; Saleh Sandoughdaran; Farzad Taghizadeh-Hesary
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

Review 3.  SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis.

Authors:  Gaurav Seth; Saira Sethi; Shristi Bhattarai; Geetanjali Saini; Chandra Bhushan Singh; Ritu Aneja
Journal:  Cancers (Basel)       Date:  2020-11-05       Impact factor: 6.639

4.  Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis.

Authors:  Wojciech Margas; Piotr Wojciechowski; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2022-08-09

5.  COVID-19: a challenge for oncology services.

Authors:  Bertrand Routy; Lisa Derosa; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2020-05-05       Impact factor: 8.110

6.  Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.

Authors:  Elissar Moujaess; Hampig Raphael Kourie; Marwan Ghosn
Journal:  Crit Rev Oncol Hematol       Date:  2020-04-22       Impact factor: 6.625
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.